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Metastasis-associated phosphatase of regenerating liver-3 (PRL-3) has pleiotropic effects in driving cancer 
progression, yet the signaling mechanisms of PRL-3 are still not fully understood. Here, we provide evidence 
for PRL-3–induced hyperactivation of EGFR and its downstream signaling cascades in multiple human can-
cer cell lines. Mechanistically, PRL-3–induced activation of EGFR was attributed primarily to transcriptional 
downregulation of protein tyrosine phosphatase 1B (PTP1B), an inhibitory phosphatase for EGFR. Func-
tionally, PRL-3–induced hyperactivation of EGFR correlated with increased cell growth, promigratory char-
acteristics, and tumorigenicity. Moreover, PRL-3 induced cellular addiction to EGFR signaling, as evidenced 
by the pronounced reversion of these oncogenic attributes upon EGFR-specific inhibition. Of clinical signif-
icance, we verified elevated PRL-3 expression as a predictive marker for favorable therapeutic response in a 
heterogeneous colorectal cancer (CRC) patient cohort treated with the clinically approved anti-EGFR antibody 
cetuximab. The identification of PRL-3–driven EGFR hyperactivation and consequential addiction to EGFR 
signaling opens new avenues for inhibiting PRL-3–driven cancer progression. We propose that elevated PRL-3 
expression is an important clinical predictive biomarker for favorable anti-EGFR cancer therapy.
Introduction
Reversible tyrosine phosphorylation is governed by the balanced 
action of protein tyrosine kinases and protein tyrosine phos-
phatases (PTPs). Dysregulation of PTP activity results in aberrant 
tyrosine phosphorylation, which is frequently implicated in the 
progression of various diseases including diabetes, rheumatoid 
arthritis, and cancer (1). Over the past decade, mounting evidence 
implicates the phosphatase of regenerating liver (PRL) family 
of PTPs in the metastatic progression of multiple human can-
cers. The first PRL associated with cancer metastasis was PRL-3 
(PTP4A3), which was found to be consistently expressed at high 
levels in all 18 human colorectal cancer (CRC) liver metasta-
ses examined, but at lower levels in the corresponding primary 
tumors and normal epithelium (2). In a recent study analyzing 
global gene expression patterns, PRL-3 was again identified as the 
most significant predictor of liver metastatic recurrence in uveal 
melanoma patients (3). These reports suggest a key role for PRL-3 
in cancer metastasis. To date, elevated PRL-3 expression has been 
correlated to the metastatic potential and poor prognosis of mul-
tiple cancer types, including colorectal, gastric, breast, ovarian, and 
lung cancers (4). Functionally, PRL-3 promotes multiple stages of 
malignant transformation including cellular proliferation, inva-
sion, motility, angiogenesis, and survival (5).
PRL-3 has been shown to increase the activity of the PI3K/AKT, 
MAPK/ERK, and/or SRC pathways in distinct cellular systems 
(5). Previously, PRL-3 was shown to promote the activation of 
AKT in DLD-1 colorectal carcinoma cells, with a concomitant 
downregulation in protein expression levels of the main negative 
regulator of AKT activity, the phosphatase and tensin homolog 
(PTEN) phosphatase (6). However, our recent report (7) suggests 
that PRL-3 could also increase AKT phosphorylation in cells 
with PTEN loss-of-function mutations, including A2780 ovar-
ian carcinoma cells (8), implying that PRL-3 might also function 
independently of PTEN. Among the best-characterized activa-
tors of PI3K/AKT signaling are the receptor tyrosine kinases 
(RTKs). EGFR/ERBB1 is the first of 4 members (ERBB1–4) in 
the ERBB RTK family. Binding of EGF or its related ligands to 
the extracellular ligand–binding domain of the ERBB family of 
receptors leads to the formation of active homo- or heterodi-
mers, which autophosphorylate each other (9). These then serve 
as hubs for the recruitment and simultaneous activation of vari-
ous signaling cascades, including the AKT and MAPK pathways, 
which play critical roles in cell proliferation, survival, adhesion, 
and migration (10). Consequentially, ERBB ligands and recep-
tors, particularly EGFR and HER2, are frequently overexpressed 
and/or mutated in many solid tumors, correlating with an unfa-
vorable prognosis, decreased survival, and altered response to 
chemotherapy (11). Interestingly, effective targeted therapies 
against many RTKs, including EGFR and HER2/NEU, invari-
ably result in the downregulation of PI3K/AKT signaling (12, 
13). Furthermore, in KRAS mutant CRC cells such as DLD-1 and 
HCT116, RTKs have been demonstrated to exert dominant con-
trol over PI3K/AKT signaling (14).
In light of these findings, we hypothesized that PRL-3 might 
activate RTKs as a proxy in activating multiple oncogenic effec-
tors, including AKT and MAPK, to drive cancer progression. 
Herein, we describe the PRL-3–induced hyperactivation of the 
EGFR and its downstream signaling effectors. The addiction of 
PRL-3–overexpressing cells and tumors to hyperactive EGFR sig-
naling was demonstrated by the hypersensitivity of their growth to 
EGFR inhibition. Our results reveal a close relationship between 
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elevated PRL-3 expression and favorable response to EGFR inhi-
bition, a key finding that could be of immediate clinical relevance 
in the stratification of patients who are likely to benefit from 
EGFR-targeted therapies.
Results
PRL-3 overexpression results in hyperactivation of EGFR and its down-
stream signaling pathways. To examine whether PRL-3 overexpres-
sion could affect RTK activity, we first engineered A431 epider-
moid carcinoma cells to stably express either EGFP (A431-vec) or 
EGFP-tagged PRL-3 (A431-PRL-3). A431 cells were chosen because 
they overexpress EGFR and represent a well-established model 
system routinely used in RTK activation and network modeling 
studies (15–18). When comparing serum-starved A431-vec and 
A431-PRL-3 cells, we noted a pronounced increase in tyrosine phos-
phorylation of multiple protein bands upon PRL-3 overexpression 
(Figure 1A, lanes 1 and 3). Of these, the most dramatic increase in 
tyrosyl phosphorylation observed was for a 165-kDa protein that 
could be further enhanced upon EGF stimulation (Figure 1A, lanes 
2 and 4, arrow). Next, using a “phospho-activated” antibody array 
against 71 unique protein tyrosine kinases (PTKs) (antibody map 
provided in Supplemental Figure 1; supplemental material avail-
able online with this article; doi:10.1172/JCI66824DS1), notable 
differences in basal activation status between A431-vec control cells 
(Figure 1B, left panel) and A431-PRL-3 cells (Figure 1B, right panel) 
were observed. Compared with A431-vec control cells, in A431-
PRL-3 cells, AXL, EGFR, and ERBB2 RTKs (spot IDs 2E/F, 3E/F, 
and 5I/J in Figure 1, B and C) had the greatest increase in tyrosyl 
phosphorylation, whereas LYN, TIE2, and ZAP70 (spot IDs 9C/D, 
12C/D, and 13I/J in Figure 1, B and C) had the greatest decrease in 
tyrosyl phosphorylation.
Since EGFR has an approximate molecular weight of 165 kDa 
and is known to be overexpressed in A431 cells, we further exam-
ined EGFR by Western blotting and found that there was increased 
activation-associated EGFR tyrosyl phosphorylation (Y1068) in 
A431-PRL-3 cells (Figure 1D), supporting our phospho-activation 
antibody array results. Phosphorylation of EGFR was consistently 
upregulated in A431-PRL-3 cells compared with A431-vec cells 
regardless of serum supplementation (data not shown). To inves-
tigate whether the increased EGFR phosphorylation correlated 
with enhanced downstream EGFR signaling in A431-PRL-3 cells, 
EGFR was immunopurified from A431-vec and A431-PRL-3 cells 
to check for binding of GRB2, an adaptor protein that couples 
EGFR activation to RAS signaling by direct interaction with 
phosphorylated Y1068 of the EGFR (19). In non-EGF–stimulated 
conditions, more GRB2 was associated with EGFR in A431-PRL-3 
compared with control A431-vec cells (Figure 1E, lanes 1 and 3). 
GRB2-associated binding protein 1 (GAB1) is a docking protein 
which, upon RTK-induced tyrosyl phosphorylation, recruits PI3K 
to RTKs to activate PI3K/AKT signaling (20). In A431-PRL-3 cells, 
GAB1 was more highly phosphorylated, with a corresponding 
increase in AKT phosphorylation (Figure 1F). In support of a 
functional increase in EGFR activity, phospho-specific antibod-
ies against different activated EGFR downstream targets, includ-
ing SRC homology 2 domain containing transforming protein 1 
(SHC), signal transducer and activator of transcription 1 (STAT1), 
E twenty-six ETS-like transcription factor 1 (ELK1), and the MAP 
kinases ERK1/2, JNK, and p38 MAPK, all showed increased phos-
phorylation in A431-PRL-3 cells compared with A431-vec cells 
(Figure 1F). These results collectively suggest that PRL-3 increased 
basal EGFR phosphorylation, activation, and downstream signal-
ing along several signaling pathways, including the MAPK, PI3K/
AKT, and STAT pathways.
PRL-3–mediated hyperactivation of EGFR is partially dependent on SRC 
activity and may not involve changes in autocrine EGFR ligand secretion. 
We next investigated the molecular mechanisms to determine 
how PRL-3 induces EGFR activation. RTK phosphorylation can 
be regulated by (a) transactivation by other kinases, (b) ligand 
binding and subsequent autoactivation, and (c) inactivation by 
intracellular RTK phosphatases. PRL-3 has previously been shown 
to activate SRC (21), a pleiotropic kinase that is known to modu-
late the activity and signaling of multiple RTKs, including EGFR, 
by direct phosphorylation (22). Specifically, SRC has been shown 
to phosphorylate Y845 of the EGFR to regulate EGFR activity 
(23). In A431 cells, PRL-3 overexpression resulted in an increase in 
phosphorylation of both EGFR Y1068 and Y845. Notably, PRL-3–
induced hyperphosphorylation of EGFR Y845 correlated with 
a decrease in inhibitory SRC Y530 phosphorylation (Figure 2A, 
lanes 1 and 2, and Figure 2B). To further investigate the involve-
ment of SRC in EGFR activation, we treated these cells with PP2, a 
well-characterized inhibitor of SRC family kinases. PP2 treatment 
resulted in an increase in inhibitory SRC Y530 phosphorylation 
in both A431-vec and A431-PRL-3 cells. Importantly, SRC inhibi-
tion corresponded with a dramatic reduction in both EGFR Y1068 
and Y845 phosphorylation in both cell lines. However, it did not 
abolish the EGFR hyperphosphorylation observed in A431-PRL-3 
cells relative to A431-vec cells (Figure 2A, lanes 3 and 4, and Figure 
2B). Based on these observations, we reasoned that SRC activity, 
though critical for sustaining EGFR phosphorylation in these 
cells, was not the major mechanism for EGFR hyperactivation 
by PRL-3. In contrast, treatment with AG-1478, a highly specific 
EGFR kinase inhibitor (24), effectively suppressed EGFR Y1068 
and Y845 phosphorylation in both cell lines (Figure 2A, lanes 5 
and 6, and Figure 2B). We next examined whether HER2, a classic 
proto-oncogenic member of the ERBB family, might be involved in 
EGFR transactivation in PRL-3–overexpressing cells. We detected a 
dramatic increase in HER2 Y1221/1222 phosphorylation in A431-
PRL-3 cells relative to A431-vec control cells (Figure 2A, lanes 1 
and 2, and Figure 2B), but this was potently inhibited upon PP2 
or AG-1478 treatment in both cell lines (Figure 2A, lanes 3–6, 
and Figure 2B). A similar observation was made for STAT5 (Fig-
ure 2A, lanes 1–6, and Figure 2B), a previously characterized SRC 
substrate (25). These results suggest that HER2, like STAT5, lies 
downstream of both SRC and EGFR kinase activities and is not 
responsible for EGFR transactivation by PRL-3.
To investigate the involvement of autocrine factors in regulating 
EGFR activation in A431-PRL-3 cells, we harvested conditioned 
culture media from A431-vec and A431-PRL-3 cells to compare 
differences in secreted autocrine factors. Using an antibody array 
(antibody map provided in Supplemental Figure 2), no differ-
ences were observed in the secretion of 41 unique growth factors 
between these 2 stable cell pools (Figure 2C), including the EGFR 
ligands amphiregulin, EGF, heparin-binding EGF-like growth fac-
tor (HB-EGF), and TGF-α (9). Collectively, these results indicate 
that the primary mechanism of PRL-3–specific EGFR hyperactiva-
tion lies upstream of SRC activity and may not involve changes in 
autocrine ligand secretion, at least for the EGFR ligands analyzed.
PRL-3 transcriptionally downregulates PTP1B, an EGFR phosphatase, 
to promote EGFR hyperphosphorylation. EGFR dephosphorylation 
is a physiologically important means of terminating recep-
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tor signaling, and inhibition of EGFR phosphatases results in 
EGFR phospho-activation (26). We next investigated the role of 
PTP1B, a well-characterized tyrosyl-directed EGFR phosphatase 
(27, 28), in PRL-3–induced EGFR hyperactivation. Immunoblot 
analysis revealed a decrease in PTP1B protein expression in 
A431-PRL-3 cells compared with A431-vec cells, concomitant 
with an increase in phosphorylated EGFR (Figure 3A). Using 
quantitative real-time PCR, we found a significant decrease in 
PTP1B mRNA levels in A431-PRL-3 cells compared with A431-
vec cells. Importantly, the extent of reduction in PTP1B mRNA 
levels correlated well with a decrease in PTP1B protein expres-
sion (Figure 3B). This result suggests that PRL-3 might be reg-
Figure 1
PRL-3 overexpression activates the EGFR in A431 cells. (A) Representative immunoblots of total lysates from serum-starved A431-vec and A431-
PRL-3 cells with or without EGF (100 ng/ml; 20 minutes) stimulation. The anti–p-Tyr blot was stripped and reprobed with an anti-GFP antibody. 
Arrow identifies a PRL-3–induced, EGF-responsive tyrosine phosphorylated 165-kDa protein. (B) Total protein lysates from A431-vec (left panel) 
or A431-PRL-3 (right panel) cells were analyzed using an antibody array against 71 unique PTKs (array map provided in Supplemental Figure 1). 
The top 3 “PRL-3–activated” or “PRL-3–inactivated” PTKs are indicated on the right, with spot IDs and gene names. (C) Arrays in B were analyzed 
using densitometry, and fold changes in individual spots were calculated after normalizing to the positive controls on each membrane (mean ± 
standard deviation, n = 2). Gene names and fold changes (PRL-3 versus vec) of the top 3 “PRL-3–activated” or “PRL-3–inactivated” PTKs are 
highlighted. (D) A431-vec or A431-PRL-3 lysates were immunoblotted with antibodies against phosphorylated EGFR (Y1068) and reprobed for total 
EGFR. GAPDH was used as a loading control. (E) After treatment as in A, lysates from A431-vec and A431-PRL-3 cells were immunoprecipitated 
(IP) with an anti-EGFR antibody and immunoblotted (IB) with anti-EGFR and anti-GRB2 antibodies. Lane pairs were run on the same gel but were 
noncontiguous. TCL, total cell lysate. (F) Various EGFR downstream signaling components were analyzed in A431-vec and A431-PRL-3 cells. GAB1 
was immunoprecipitated and analyzed using a phosphotyrosine antibody. Blots were probed with the various antibodies as indicated. GAPDH was 
used as a loading control.
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ulating PTP1B expression at the transcript level. To examine 
whether PRL-3–driven downregulation of PTP1B was a gen-
eral phenomenon, this finding was validated in 3 other human 
cancer cell lines of different tissue origins and with differential 
EGFR protein expression levels: MDA-MB-468 breast cancer 
cells (high EGFR levels), HCT116 colon cancer cells (moderate 
EGFR levels), and A2780 ovarian cancer cells (low EGFR levels) 
(Supplemental Figure 3A). Pooled colonies of MDA-MB-468 
breast cancer cells overexpressing EGFP-PRL-3 (MDA-MB-468-
PRL-3) revealed higher EGFR phosphorylation and reduced 
PTP1B protein expression compared with control cells (MDA-
MB-468-vec) (Figure 3C). Again, the expression of PTP1B mRNA 
and protein was downregulated by similar degrees in these cells 
(Figure 3D). To further validate the influence of PRL-3 on EGFR 
activation, we analyzed the EGFR activation status in HCT116 
cells, which abundantly express endogenous PRL-3, upon stable 
expression of either a scrambled (shSCR) or a PRL-3–specific 
shRNA (shPRL-3) construct. EGFR phosphorylation was clearly 
reduced upon knockdown of endogenous PRL-3, correlating 
with an upregulation of PTP1B expression levels (Figure 3E). 
Consistently, we also observed a decrease in PTP1B expression 
in A2780 cells upon PRL-3 overexpression (Supplemental Figure 
3B). However, phosphorylated EGFR could not be detected in 
our A2780 immunoblots, likely due to the low EGFR expression 
in this cell line (Supplemental Figure 3A). Collectively, these 
results suggest a close relationship between the suppression of 
PTP1B expression and EGFR hyperphosphorylation in response 
to PRL-3 overexpression.
To verify whether the downregulation of PTP1B was caused by 
PRL-3 overexpression and not by a negative feedback loop due to 
EGFR hyperactivation, we treated MDA-MB-468-vec and MDA-
MB-468-PRL-3 cells with 3 distinct EGFR inhibitors: AG-1478, 
Figure 2
PRL-3–induced EGFR activation is partially dependent on SRC activity and may not involve changes in autocrine stimulation. (A) Representative 
immunoblots from A431-vec and A431-PRL-3 cells treated with DMSO (16 hours), PP2 (16 hours), or AG-1478 (75 minutes) before lysates were 
collected and analyzed. Phosphoprotein blots were stripped and reprobed for their total protein counterparts. GAPDH was used as a loading 
control. (B) Quantitation of selected immunoblot densities in A. Phosphoprotein band densities were normalized to their total protein counterparts. 
Black bars represent A431-vec; white bars represent A431-PRL-3. (C) Serum-free conditioned media (20 hours) from A431-vec and A431-PRL-3 
cells were collected and analyzed using an antibody array against 41 different growth factors (array map provided in Supplemental Figure 2). No 
significant differences were quantitated using densitometry (data not shown).
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013 3463
erlotinib (29), or cetuximab (30). These inhibitors failed to restore 
the reduced PTP1B levels in the MDA-MB-468-PRL-3 cells back 
to those in the MDA-MB-468-vec control cells (Supplemental Fig-
ure 3C), suggesting that PRL-3–induced PTP1B downregulation 
lies upstream of EGFR hyperphosphorylation. Next, to validate 
whether alterations in PTP1B expression are causally involved in 
PRL-3–induced EGFR hyperphosphorylation, MDA-MB-468-vec 
and MDA-MB-468-PRL-3 cells, which demonstrated the largest 
difference in PTP1B levels upon forced PRL-3 expression (Figure 
3C), were transiently transfected with either FLAG-tagged PTP1B 
or PTP1B-specific siRNA sequences. When we rescued PTP1B 
expression in MDA-MB-468-PRL-3 cells using transient FLAG-
PTP1B overexpression, EGFR phosphorylation decreased to the 
levels observed in MDA-MB-468-vec control cells (Figure 3F). This 
effect was not specific to PRL-3–overexpressing cells, as PTP1B 
overexpression in MDA-MB-468-vec control cells also resulted in 
EGFR dephosphorylation (Supplemental Figure 3D). Conversely, 
PTP1B depletion in MDA-MB-468-vec cells resulted in an increase 
Figure 3
PRL-3 induces EGFR hyperphosphorylation via PTP1B downregulation. (A) A431-vec and A431-PRL-3 cells were analyzed for PTP1B expression 
and EGFR (Y1068) phosphorylation. Numbers below EGFR immunoblots reflect the ratio of p-EGFR/EGFR blot densities. GAPDH was used 
as a loading control. (B) Comparison of relative PTP1B mRNA expression (biological triplicate; mean ± standard deviation; paired Student’s 
t test, *P = 0.012) versus protein expression (densitometric quantitation of PTP1B bands in A) in A431-vec and A431-PRL-3 cells. GAPDH mRNA 
expression and protein expression, respectively, were used for normalization. (C) MDA-MB-468-vec and MDA-MB-468-PRL-3 cells were analyzed 
for PTP1B expression and EGFR phosphorylation as in A. (D) Comparison of relative PTP1B mRNA expression (mean ± standard deviation; 
Student’s t test, **P < 0.001) versus protein expression in MDA-MB-468-vec and MDA-MB-468-PRL-3 cells, analyzed as in B. (E) HCT116 cells 
stably expressing scrambled (shSCR) or PRL-3–specific shRNA (shPRL-3) were analyzed for PTP1B expression and EGFR phosphorylation 
as in A. (F) MDA-MB-468-vec and MDA-MB-468-PRL-3 cells transiently transfected (18 hours) with either empty vector (VC) or FLAG-tagged 
PTP1B constructs were analyzed for EGFR phosphorylation. (G) MDA-MB-468-vec and MDA-MB-468-PRL-3 cells transiently transfected (72 
hours) with control nonspecific siRNA (siSCR) or PTP1B-targeting siRNA (siPTP1B) were analyzed for EGFR phosphorylation. T cell PTP 
(TC-PTP), the closest homolog of PTP1B, served as a control for siRNA specificity. GAPDH was used as a loading control. (H) Stratified PRL-3 
mRNA expression levels were negatively correlated to raw PTP1B mRNA expression levels in metastatic breast cancer patient samples (n = 204; 
Mann-Whitney U test, P = 0.001).
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in EGFR phosphorylation to the levels seen in MDA-MB-468-
PRL-3 cells (Figure 3G). Notably, depletion of PTP1B in MDA-
MB-468-PRL-3 cells resulted in further enhancement of EGFR 
hyperphosphorylation (Supplemental Figure 3E), suggestive of a 
dose dependence of EGFR phosphorylation on PTP1B expression. 
Although the precise molecular mechanism remains to be defined 
in future studies, our results here suggest that PRL-3 downregu-
lates PTP1B in order to inhibit EGFR dephosphorylation, thereby 
resulting in EGFR hyperphosphorylation.
PRL-3 and PTP1B mRNA expression is inversely correlated in a cohort of 
metastatic breast cancer patients. To investigate the clinical relevance 
of the relationship between PRL-3 and PTP1B, two previously unre-
lated phosphatases, we analyzed a publicly available microarray 
dataset generated from a cohort of 204 metastatic breast cancer 
patients. In this dataset, HB-EGF was identified as a key mediator 
of breast cancer metastasis to the brain, implicating EGFR signal-
ing in the metastatic dissemination of primary tumors in these 
patients (31). Consistent with the prometastatic role of PRL-3, we 
found that patients with high PRL-3 mRNA expression had signifi-
cantly shorter disease-free survival times (median survival = 20.5 
months, 95% CI = 16.0–25.0) compared with those with low PRL-3 
mRNA expression in their primary tumors (median survival = 
28.1 months, 95% CI = 24.4–31.8), with a hazard ratio (HR) of 1.45 
(95% CI = 1.05–2.00, P = 0.024) between them. Importantly, PRL-3 
and PTP1B transcript levels in this dataset were significantly 
and inversely correlated with each other (Spearman’s rank test, 
Figure 4
EGFR-specific inhibitors block PRL-3–induced dissolution of stress fibers and F-actin enrichment at membrane protrusions. (A–D) MDA-MB-
468-vec (A and B) or MDA-MB-468-PRL-3 (C and D) cells were seeded on glass coverslips and incubated with 0.1% DMSO (A and C) or 2 μM 
erlotinib (B and D) 16 hours prior to fixing. Fixed cells were stained with phalloidin to visualize F-actin stress fibers. Scale bars: 20 μm. (E–H) 
MDA-MB-468-vec (E and F) or MDA-MB-468-PRL-3 (G and H) cells were seeded on glass coverslips and incubated with PBS (E and G) or 100 
nM cetuximab (F and H) 16 hours prior to fixing. Fixed cells were stained with phalloidin to visualize F-actin enrichment. Arrows indicate sites of 
F-actin–rich membrane projections. Green, EGFP signal; red, F-actin. Scale bars: 20 μm.
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Figure 5
PRL-3–overexpressing cells are hypersensitive to EGFR-specific inhibitors. (A) Representative immunoblots of serum-starved A431-vec and A431-PRL-3 
cells treated with DMSO or AG-1478 (AG) 75 minutes before lysis. Lane pairs were run on the same gel but were noncontiguous. Normalized densi-
tometric ratios of phosphoproteins/total proteins are indicated below selected blots. (B) Representative immunoblots of serum-starved A431-vec and 
A431-PRL-3 treated with PBS or cetuximab (CTX) 24 hours before lysis. Lane pairs were run on the same gel but were noncontiguous. (C) Represen-
tative immunoblots of serum-starved MDA-MB-468-vec and MDA-MB-468-PRL-3 cells treated with DMSO, AG-1478 (75 minutes), or erlotinib (3 hours) 
before lysis. (D) A431-vec or A431-PRL-3 cell growth after 48-hour exposure to DMSO, cisplatin, AG-1478, erlotinib, or cetuximab in 0.5% FBS medium 
(mean ± standard deviation; n = 3; unpaired Student’s t test, *P < 0.05, **P < 0.001). Black bars, A431-vec; white bars, A431-PRL-3. Arrows indicate a 
hypersensitive response. (E) A431-vec and A431-PRL-3 cell colony score after 11 days of treatment with PBS or 20 nM cetuximab in 10% FBS medium 
(mean ± standard deviation; n = 2; unpaired Student’s t test, *P < 0.05). Arrow indicates a hypersensitive response. Representative images of colony for-
mation are shown in the right panel. (F) Growth curves of A431-vec or A431-PRL-3 xenograft tumors treated i.p. with 1 mg cetuximab or 200 μl PBS twice 
weekly for 2 weeks (mean ± standard deviation; *P < 0.05). (G) Comparison of day 14 tumor volumes from F (Student’s t test, *P < 0.05, **P < 0.001).
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r = –0.168, P = 0.016). Indeed, patients expressing high levels of 
PRL-3 had significantly lower PTP1B expression (mean ± SEM = 
212.1 ± 10.3) compared with those expressing low levels of PRL-3 
(mean ± SEM = 298.0 ± 18.4; Mann-Whitney U test, P = 0.001) (Fig-
ure 3H), indicating an antagonistic relationship between PRL-3 
and PTP1B expression in clinical metastatic breast cancer samples 
and supporting our in vitro observations.
PRL-3–induced stress fiber dissolution and F-actin enrichment at sites 
of membrane protrusions can be blocked by EGFR inhibition. Since the 
above-described patient dataset consisted of samples from met-
astatic breast cancer patients, we next investigated the biological 
consequences of EGFR activation by PRL-3 on the motile pheno-
type of the metastatic breast cancer cell line MDA-MB-468. Cell 
migration involves the orchestrated assembly and disassembly 
of actin filaments (32). Using immunofluorescence analysis, we 
observed a marked decrease in cytoskeletal F-actin stress fibers 
in MDA-MB-468-PRL-3 cells (Figure 4C) compared with MDA-
MB-468-vec control cells (Figure 4A). This observation is in agree-
ment with previously published results (6) and is consistent with 
increased cell migration (33). To validate whether EGFR activation 
by PRL-3 could be involved in the decrease of actin stress fibers, 
we used erlotinib to treat these cells. Erlotinib treatment did not 
affect stress fiber formation in MDA-MB-468-vec cells (Figure 4B), 
but did effectively block stress fiber dissolution in MDA-MB-468-
PRL-3 cells (Figure 4D) and returned these cells to a similar state 
as seen in the vector control cells (Figure 4A). Besides modulation 
of stress fiber assembly, EGF stimulation has been previously 
shown to stimulate cell migration by the formation of actin-rich 
membrane protrusions at the leading edge of migratory cells in a 
PI3K-dependent manner (34). Compared with MDA-MB-468-vec 
cells (Figure 4E), we noted a pronounced increase in F-actin–rich 
membrane protrusions at the leading edge of MDA-MB-468-PRL-3 
cells (Figure 4G). Similarly, PRL-3–induced membrane projections 
were essentially blocked by EGFR inhibition using cetuximab (Fig-
ure 4H). Importantly, whereas there was no observed difference 
with regard to both stress fiber formation and membrane protru-
sions in MDA-MB-468-vec cells upon EGFR inhibition (Figure 4, 
A, B, E, and F), MDA-MB-468-PRL-3 cells responded dramatically 
to EGFR inhibition (Figure 4, C, D, G, and H). Collectively, these 
results suggest that PRL-3 enhances stress fiber disassembly and 
induces leading-edge F-actin–rich membrane protrusions in an 
EGFR-dependent manner.
PRL-3–overexpressing cells are hypersensitive to EGFR inhibition. 
Because PRL-3–overexpressing cells displayed enhanced activa-
tion of the signaling components involved in prosurvival and 
proliferative pathways, including AKT and ERK1/2, we investi-
gated whether inhibition of EGFR could potentially abrogate 
these oncogenic events. Treatment of A431-vec and A431-PRL-3 
cells with AG-1478 effectively reduced AKT and ERK1/2 phos-
phorylation levels in both cell types. Unexpectedly, the reduc-
tion in phosphorylated AKT and ERK1/2 upon EGFR kinase 
inhibition by AG-1478 was much greater in A431-PRL-3 cells 
than in A431-vec control cells (Figure 5A, lanes 3 and 4). To 
confirm this phenomenon, we treated A431-vec and A431-
PRL-3 cells with a different EGFR inhibitor, cetuximab. Treat-
ment with a physiologically relevant cetuximab dose potently 
inhibited EGFR phosphorylation in both cell lines. Signifi-
cantly, phosphorylated AKT and ERK1/2 were again reduced 
by a greater extent in cetuximab-treated A431-PRL-3 cells 
compared with A431-vec cells (Figure 5B, lanes 3 and 4). To 
rule out cell-specific effects, we treated MDA-MB-468-vec and 
MDA-MB-468-PRL-3 cells with the EGFR inhibitors AG-1478 
and erlotinib. In agreement with previous reports (35, 36), 
no significant changes in phosphorylated AKT were observed 
upon EGFR inhibition in these PTEN-deficient MDA-MB-468 
cells (Figure 5C, lanes 1–6). However, phosphorylated ERK1/2 
was decreased by a greater extent in MDA-MB-468-PRL-3 cells 
compared with MDA-MB-468-vec cells upon EGFR inhibition 
Figure 6
High PRL-3 expression levels correlate with a favorable therapeutic response in cetuximab-treated CRC patients. PRL-3 mRNA expression levels 
positively correlate with (A) objective response (n = 68; Student’s t test, P < 0.01) and (B) disease control (n = 68; Student’s t test, P < 0.001) in 
cetuximab-treated CRC patients. Note that the relative mRNA expression of PRL-3 is presented on a logarithmic (log2) scale. (C) High PRL-3 mRNA 
expression is associated with longer progression-free survival times in cetuximab-treated CRC patients (n = 68; Cox regression analysis, P < 0.05).
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(Figure 5C, lanes 3–6). Collectively, these results suggest that 
the hypersensitive response to EGFR inhibition in PRL-3–over-
expressing cells is likely a general property.
The hypersensitivity of PRL-3–expressing cells to EGFR inhibi-
tion was reminiscent of “oncogene addiction,” a phenomenon in 
which the growth and survival of cancer cells may be overly depen-
dent on one or a few dominant, driver oncogenes (37). We thus 
hypothesized that the inhibition of EGFR in such PRL-3–driven 
“EGFR-addicted” cells might be a specific and therapeutically 
exploitable means to inhibit their growth. We first analyzed cell 
growth in the presence of the general proliferation inhibitor cis-
platin (38) or EGFR-specific inhibitors (AG-1478, erlotinib, and 
cetuximab). In the absence of inhibitor treatment, A431-PRL-3 cells 
grew significantly faster than A431-vec cells (Figure 5D). Cisplatin 
treatment resulted in an even decrease in both A431-vec and A431-
PRL-3 cell proliferation (Figure 5D), without any PRL-3–specific 
hypersensitive response to this general proliferation inhibitor. In 
sharp contrast, all 3 EGFR-specific inhibitors (AG-1478, erlotinib, 
and cetuximab) led to a significantly greater decrease in A431-
PRL-3 cell growth compared with A431-vec cells (Figure 5D; red 
arrows indicate a hypersensitive response). Interestingly, chemi-
cal inhibition of SRC, AKT, or ERK1/2 (using PP2, perifosine, or 
U0126, respectively), despite inhibiting A431-PRL-3 cell prolifer-
ation, failed to reproduce such a PRL-3–induced hypersensitive 
response (Supplemental Figure 4). Next, we used a monolayer 
clonogenicity assay to investigate the ability of cetuximab to inhibit 
colony formation of A431-vec and A431-PRL-3 cells. Although 
A431-PRL-3 cells formed more colonies than A431-vec cells under 
control (PBS-treated) conditions, this was significantly reversed 
upon cetuximab treatment (Figure 5E). Finally, to test whether 
PRL-3 could endow cancer cells with increased anti-EGFR agent 
susceptibility in vivo, we treated established xenograft tumors of 
A431-vec or A431-PRL-3 cells in nude mice with PBS or cetuximab 
twice weekly for 2 weeks and monitored tumor growth. We found 
that A431-vec tumors grew slower than A431-PRL-3 tumors in PBS-
treated mice, yet this was markedly reversed in cetuximab-treated 
mice (Figure 5F). Importantly, an analysis of tumor volumes at 
the end of the experiment (day 14) revealed significantly smaller 
A431-PRL-3 tumors compared with A431-vec tumors in the cetuxi-
mab-treated mice (Figure 5G). In summary, our results suggest that 
PRL-3 induces hypersensitivity to EGFR inhibition both in vitro 
and in vivo due to hyperactive EGFR signaling addiction.
PRL-3 expression is a predictor of a favorable therapeutic response in 
cetuximab-treated CRC patients. To investigate the clinical relevance of 
our observations, we tested whether PRL-3 mRNA expression levels 
correlated with tumor sensitivity to anti-EGFR drug treatment in a 
microarray dataset from a CRC patient cohort prior to treatment 
with cetuximab monotherapy (39). Patients’ tumors that responded 
better to cetuximab therapy (complete or partial response) had a 
significantly higher median expression level of PRL-3 compared 
with those that did not respond to the same treatment (P < 0.01) 
(Figure 6A). Furthermore, a significantly higher median expression 
level of PRL-3 was also observed in patients with controlled disease 
as compared with patients who had progressive disease (P < 0.001) 
(Figure 6B). Indeed, patients with a high level of PRL-3 expres-
sion had an overall response rate (ORR) of 17% and a disease con-
trol rate (DCR) of 53%, both of which were higher than what was 
observed in patients with a low level of PRL-3 expression (ORR = 0%, 
P = 0.026; DCR = 19%, P = 0.005). Importantly, high PRL-3 expres-
sion was associated with a longer progression-free survival rate in 
cetuximab-treated patients compared with those who had low PRL-3 
expression (HR = 0.61, 95% CI = 0.39–0.96, P = 0.034) (Figure 6C). 
Our clinical observations are in agreement with a previous report 
(40) showing that elevated PRL-3 (PTP4A3) expression ranked 
first, sixth, and fourth (of 110 genes) in terms of correlation with 
a favorable objective response, disease control, and progression-
free survival, respectively, in an independent cetuximab-treated 
CRC patient cohort. Collectively, these clinical results support our 
in vitro observations that a high level of PRL-3 expression induces 
sensitivity to EGFR inhibition due to addiction to activated EGFR. 
Interestingly, analysis of PRL-3 expression levels in a microarray 
dataset of gefitinib-sensitive or gefitinib-resistant NSCLC cell lines 
(41) also revealed significantly higher PRL-3 expression levels in 
gefitinib-sensitive cells (Supplemental Figure 5). Taken together, 
our results suggest that PRL-3–induced addiction to EGFR might 
be a general property in multiple cancer types and indicate that 
PRL-3 expression levels could be a useful predictive biomarker for 
favorable anti-EGFR therapy response in patients.
Figure 7
Proposed model of PRL-3–induced oncogenic addiction to hyperactivated EGFR. (A and B) Compared with non-PRL-3–overexpressing cells (A), 
PRL-3 overexpression (B) induces constitutive hyperactivation of EGFR via the downregulation of PTP1B, promoting the growth of “EGFR-ad-
dicted” cancer cells. (C and D) Compared with non-PRL-3–overexpressing cells (C), PRL-3–overexpressing EGFR-addicted cells (D) are hyper-
sensitive to EGFR inhibition.
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Discussion
In this study, we present evidence for PRL-3–induced hyperacti-
vation of EGFR and its downstream effectors. We characterized 
the downregulation of an EGFR phosphatase, PTP1B, as a key 
mechanism involved in PRL-3–mediated hyperphosphorylation of 
EGFR. Indeed, an inverse relationship was found between PRL-3 
and PTP1B expression in various cell lines as well as in clinical 
breast cancer samples, thereby establishing a novel relationship 
between these two phosphatases. Functionally, we found that phar-
macological inhibition of EGFR signaling could potently inhibit 
PRL-3–enhanced cell and tumor growth, revealing a profound 
hypersensitivity of PRL-3–overexpressing cells and tumors to EGFR 
inhibition. Clinically, the translational relevance of these findings 
is that elevated PRL-3 expression could predict a favorable anti-
EGFR therapeutic response in CRC patients, in corollary suggest-
ing a novel approach to the inhibition of dual PRL-3/EGFR–posi-
tive tumors by targeting PRL-3–induced EGFR addiction. Figure 7 
summarizes our working model on how PRL-3 causes hyperactiva-
tion of oncogenic EGFR signaling, as well as the hypersensitivity of 
such EGFR-addicted cancer cells to EGFR inhibition.
The aberrant activation of RTKs has been linked to malignant 
progression of many human cancers (42). Our results suggest that 
PRL-3 exhibits pleiotropic signaling by activating EGFR, a key 
initiator of multiple signaling cascades (10). Despite pronounced 
EGFR activation by PRL-3, we noted that the extent of increase 
in EGFR phosphorylation did not correlate linearly with that of 
the various downstream effectors analyzed (Figure 1F). It could be 
that our use of pooled cell populations, the concurrent downreg-
ulation of several kinase activities (including LYN, TIE2, and ZAP-
70) (Figure 1, B and C), and/or the existence of negative feedback 
loops (43) resulted in a “masking” of the linearity between EGFR 
activation and downstream pathway activity in response to PRL-3 
overexpression. Nonetheless, our results herein provide a potential 
explanation for previous reports of PRL-3–mediated activation of 
the PI3K/AKT, SRC/STAT, and RAS/MAPK pathways (5), all of 
which lie downstream of RTK signaling (44).
PTP1B has been reported to reduce the phosphorylation of 
multiple EGFR signaling pathway components, including PLC-
γ1, GAB1, SHP2, SHP, and EGFR itself (45). Although the involve-
ment of other EGFR phosphatases (26) cannot be discounted, 
our study suggests that PTP1B is the primary EGFR phosphatase 
causally involved in PRL-3–driven EGFR hyperphosphorylation. 
The reduced levels of PTP1B in A431 and MDA-MB-468 cells 
overexpressing PRL-3 and the accumulation of PTP1B in PRL-3–
depleted HCT116 cells were, in each case, concomitant with an 
increase or decrease in EGFR phosphorylation, respectively. Fur-
thermore, changes in PTP1B mRNA expression alone, as sup-
ported by overexpression “rescue” experiments and siRNA-medi-
ated depletion (Figure 3, F and G), appear sufficient to phenocopy 
PRL-3–induced EGFR hyperphosphorylation. PTP1B expression is 
regulated by several transcription factors, including YB1 (46), HIF 
(47), and the EGR1 and SP family of transcription factors (48). It 
is plausible that PRL-3 suppresses PTP1B mRNA expression via 
the regulation of some of these transcription factors. Alternatively, 
in light of the recently characterized role of PRL-3 as an epige-
netic regulator (49), PRL-3 might induce modifications on the 
PTP1B promoter/enhancer locus to suppress PTP1B transcription. 
Although further studies are required to clarify the precise mecha-
nism of PTP1B mRNA downregulation by PRL-3, our results lend 
weight to the existence of a PRL-3/PTP1B/EGFR regulatory axis.
Despite the downregulation of PTP1B, which is also an SRC-
Y530 phosphatase (50), PRL-3 was still able to decrease SRC-Y530 
inhibitory phosphorylation and induce SRC activation. The reg-
ulation of SRC-Y530 phosphorylation is complex, with at least 2 
kinases and 5 phosphatases known to regulate SRC-Y530 phos-
phorylation (51). In agreement with previous reports (52), we 
observed that PRL-3 overexpression in A431 cells resulted in the 
downregulation of CSK, an SRC-Y530–directed kinase (data not 
shown). Thus, it is likely that PRL-3 activates SRC via such alterna-
tive, non-PTP1B–dependent pathways. Although SRC was found 
to be a key regulator of EGFR activation (Figure 2, A and B), it was 
not the primary mechanism for PRL-3–induced EGFR hyperacti-
vation. Interestingly, besides activating the EGFR, SRC is also a 
downstream signal transducer from activated EGFR (53). In light 
of these observations, we propose that hyperactivation of EGFR 
by PRL-3 via PTP1B downregulation reflects an “umbrella effect,” 
wherein activation of an upstream kinase (EGFR) promotes tum-
origenesis by activation of multiple downstream oncogenic effec-
tors — a phenomenon that could constitute a key node of PRL-3 
oncogenic signaling (Figure 7). In agreement with this model, 
inhibition of SRC, AKT, or ERK1/2 kinases individually failed 
to generate any hypersensitive response in PRL-3–overexpressing 
cells (Supplemental Figure 4), likely due to the synergism between 
these pathways downstream of EGFR in regulating cellular growth 
and/or survival.
Most importantly, we present clinical evidence that high levels 
of PRL-3 expression induce sensitivity to EGFR inhibition. Indeed, 
high expression of PRL-3 in CRC patient tumors was a predictive 
marker of a favorable anti-EGFR therapeutic response to cetuxi-
mab monotherapy (Figure 6). Our result is consistent with a recent 
study by Baker et al. (40) investigating the expression signatures 
of 110 preselected genes in the cetuximab therapeutic response 
in CRC patients, where they identified elevated PRL-3 (PTP4A3) 
expression to be strongly associated with a favorable objective 
response, disease control, and progression-free survival. These 
independent results provide substantial support for our clinical 
findings that elevated PRL-3 expression is a predictive marker of 
a favorable anti-EGFR therapeutic response. Such dependence of 
PRL-3–expressing cells on EGFR signaling is reminiscent of the 
concept of “oncogene addiction” (37). The key implication of 
this concept is that terminating the signaling of a critical, hyper-
activated pathway on which cancer cells have become dependent 
should have detrimental effects on cancer cell growth and survival, 
while sparing normal cells less reliant on these pathways. Many 
oncogenes have been described to confer such addiction (54). For 
instance, in non–small-cell lung carcinoma (NSCLC), activating 
mutations in EGFR or increased EGFR gene copy numbers have 
been found to both predict and underlie a better response to ther-
apy using gefitinib, a clinical EGFR antagonist (55). Interestingly, 
we found higher expression of PRL-3 in gefitinib-sensitive com-
pared with gefitinib-resistant NSCLC cell lines (Supplemental Fig-
ure 5), suggesting that PRL-3–induced addiction to EGFR might 
be a general property in multiple cancer types.
Targeting oncogene addiction has been proven to be a viable and 
effective approach in cancer therapy (56, 57). Here, we propose that 
PRL-3 hyperactivation of EGFR induces a therapeutically exploit-
able addiction to the receptor (Figure 7). Although further experi-
mentation will be required to validate such dependence in different 
cancer models, our results suggest that targeting EGFR addiction 
presents an exciting and, given the availability of clinical anti-
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at the following final concentrations: tryphostin AG-1478 (2 μM; Calbi-
ochem), cetuximab (10 nM; Zuellig Pharma), erlotinib (2 μM; LC Labs), 
PP2 (5 μM; Sigma-Aldrich), perifosine (1 μM; LC Labs), U0126 (10 μM; 
LC Labs), and cisplatin (1 μg/ml; Pfizer). DMSO (0.1% final; Merck) and 
PBS (0.033% final) were used as negative controls for inhibitor treatments.
Western blot analysis. Western blotting was performed as described (64). 
Membranes were stained with antibodies against AKT, p-AKT S473, EGFR, 
p-EGFR Y845, p-EGFR Y1045, p-EGFR Y1068, p-ELK1 S383, ERK1/2, 
p-ERK1/2 T202/Y204, GAB1, GFP, GRB2, HER2, p-HER2 Y1221/2, PTP1B, 
SRC, p-SRC Y530, STAT5, p-STAT5 Y694 (all from Cell Signaling Tech-
nology), GAPDH, p-Tyr clone 4G10 (both from Millipore), ERK1, p-JNK 
T183/Y185, p-p38 T180/Y182, p-STAT1 Y701 (all from BD Biosciences), 
p-SHC Y239/240 (Santa Cruz Biotechnology Inc.), TC-PTP (R&D Systems), 
or PRL-3 (64), followed by the appropriate secondary HRP-conjugated anti-
bodies (Jackson ImmunoResearch Laboratories). The membranes were visu-
alized using a chemiluminescent substrate (Thermo Scientific).
Antibody arrays. For the RTK activation study, antibody arrays against 
71 unique tyrosine kinases (RayBio; catalog AAH-PRTK-1-2) were used 
according to the manufacturer’s protocol. Cell lysates (1.2 mg) were added 
to each membrane. Spot quantitation was done using a GS-700 Imaging 
Densitometer (Bio-Rad), with a fixed volume size for all spots being com-
pared, and mean densities were calculated for each spot in duplicate (Sup-
plemental Table 1; antibody map shown in Supplemental Figure 1). For 
the secreted growth factor analysis, 1 ml of conditioned media from cells 
in DMEM without FBS (24-hour incubation) was added to antibody arrays 
against 41 unique growth factors (RayBio; catalog AAH-GF-1) and pro-
cessed according to the manufacturer’s protocol. The growth factor array 
antibody map is provided in Supplemental Figure 2.
qRT-PCR. RNA was extracted using an RNeasy Mini Kit (QIAGEN) 
according to the manufacturer’s instructions, and 1 μg was used for reverse 
transcription (Invitrogen). For qPCR, 100 ng of cDNA was amplified using 
a TaqMan Gene Expression Assay Mix with primers specific for human 
PTP1B/PTPN1 or GAPDH (Applied Biosystems). Real-time PCR was per-
formed in triplicate wells using the 7500 Fast Real-Time PCR system 
(Applied Biosystems).
Immunofluorescence. Cells grown on coverglasses (Marienfeld-Superior) 
were treated with cetuximab (100 nM) or erlotinib (2 μM) 16 hours prior 
to fixation in 4% paraformaldehyde. Immunofluorescence microscopy was 
performed as previously described (64). For F-actin visualization, cells were 
stained with Alexa Fluor 568 phalloidin (Invitrogen) according to the man-
ufacturer’s protocol.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell growth 
assay. Cells (2 × 103) were seeded in 10% FBS medium, placed in triplicate 
wells of a 96-well plate, and allowed to attach overnight. The medium was 
then replaced with 0.5% FBS medium in the presence or absence of various 
inhibitors and left to incubate for 48 hours. The medium was subsequently 
aspirated and replaced with 200 μl of 0.5% FBS medium containing MTT 
(0.2 mg/ml; Sigma-Aldrich) and left to incubate for 4 hours at 37°C at 5% 
CO2. Then, the supernatant was aspirated, 150 μl of DMSO was added 
to each well, and absorbance was measured at 595 nm. All experiments 
were done in triplicate and standard deviations were obtained. Results are 
expressed as the ratio of cell viability, calculated as: (absorbance of inhib-
itor-treated well minus absorbance of cell-free control)/(absorbance of 
control-treated well minus absorbance of cell-free control). Results were 
normalized to A431-vec DMSO-treated cells. No significant difference 
in cell proliferation was observed for A431-vec or A431-PRL-3 cells when 
treated with 0.1% DMSO (solvent for AG-1478 and erlotinib) or 0.033% 
PBS (solvent for cetuximab) (data not shown).
Monolayer clonogenicity assay. Three hundred cells were seeded in 10% FBS 
medium, placed into 10-cm dishes, and allowed to attach overnight. The 
EGFR drugs (58), readily translatable therapeutic option in tumors 
overexpressing PRL-3. This is especially pertinent, given that no 
anti–PRL-3 agents have reached clinical trials, despite promising 
preclinical results (59, 60). In view of the observation that many car-
cinoma types, including lung, breast, and colon, display heightened 
EGFR activity, and given the clinical correlation of EGFR activity 
to tumor recurrence and shorter patient survival (11), the activa-
tion of EGFR by PRL-3 could be a key factor in cancer progression. 
Our results warrant further research on the validation of PRL-3 
overexpression as a predictive biomarker for a favorable response 
to anti-EGFR therapy and propose EGFR inhibition as a viable and 
readily translatable therapeutic approach to effectively curtail the 
apparent synergy between PRL-3 and EGFR oncogenes.
Methods
Plasmids and siRNAs. The pEGFP-C1-PRL-3 construct has been described 
previously (61). Full-length PTP1B was PCR amplified from Addgene 
plasmid 8601/pJ3H-PTP1B (62) using primers containing a BamHI site 
(5′-CGGATCCATGGAGATGGAAAAGGAGTTC-3′; forward) or a NotI 
site (5′-TGCGGCCGCTATGTGTTGCTGTTGAACAGG-3′; reverse). PCR 
products were cloned into plasmid pXJ40-FLAG, a FLAG-tagged expres-
sion vector provided by Graeme Guy (Institute of Molecular and Cell Biol-
ogy, Singapore) to generate pFLAG-PTP1B. All plasmids were verified by 
sequencing. Expression vectors encoding PRL-3–directed (5′-TTCTCGG-
CACCTTAAATTATT-3′) or nontargeting scrambled shRNA sequences were 
commercially sourced (QIAGEN). siRNA against PTP1B (5′-CUUCCUAA-
GAACAAAAACC-3′) were synthesized (1st Base) based on a previously vali-
dated sequence (63).
Cell culture and transfections. A2780 ovarian carcinoma cells and HCT116 
colorectal carcinoma cells (ATCC) were routinely cultured in RPMI-1640 
medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% anti-
biotic-antimycotic. A431 epidermoid carcinoma cells and MDA-MB-468 
breast adenocarcinoma cells (ATCC) were grown in DMEM 4,500 mg/l 
high-glucose medium supplemented with 10% FBS, 2 mM L-glutamine, 
and 1% antibiotic-antimycotic. Cells were cultured in sterilized tissue cul-
ture–treated vessels at 37°C with 5% CO2 and 95% humidity. Stable cell lines 
expressing EGFP (vec) or EGFP-PRL-3 (PRL-3) were generated by transfec-
tion of cells with pEGFP-C1 vector (Clontech) or pEGFP-C1-PRL-3 con-
structs using Lipofectamine 2000 (Invitrogen), followed by selection in 1 
mg/ml neomycin (Sigma-Aldrich) for 2 weeks to obtain pooled cell popula-
tions possessing greater than or equal to 90% GFP positivity under Eclipse 
TE2000-U fluorescence microscopy (Nikon). HCT116 cells stably express-
ing shRNA constructs were similarly generated, but were selected using 1 
μg/ml puromycin (Sigma-Aldrich) instead. For transient overexpression, 
cells were transfected with pFLAG-PTP1B or vector control plasmids for 
18 hours using JetPrime (Polyplus Transfection) according to the manufac-
turer’s protocol. Plasmid amounts were titrated (250 ng) to achieve FLAG-
PTP1B overexpression in MDA-MB-468-PRL-3 cells matching the endoge-
nous PTP1B level in MDA-MB-468-vec cells as closely as possible (rescue 
experiment). For siRNA transfection, 10 nM siRNA (final) was added to the 
cells previously seeded overnight in 12-well plates using JetPrime reagent 
according to the manufacturer’s protocol. Fresh medium was replaced 24 
hours later, and the cells were incubated for another 48 hours before anal-
ysis. We found this siRNA transfection condition sufficient to deplete the 
expression of PTP1B in MDA-MB-468-vec cells to match the endogenous 
PTP1B level in MDA-MB-468-PRL-3 cells (“rescue” experiment).
Treatments. For EGF stimulation, cell monolayers (80% confluent) were 
rinsed in PBS once before incubation in serum-free media for 16 hours. 
Recombinant EGF (100 ng/ml; Peprotech) was subsequently added 20 
minutes prior to lysis. Unless otherwise specified, inhibitors were used 
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Jackson Laboratory) and allowed to grow until tumor volumes reached 
30–40 mm3, after which the mice were divided into 2 groups and treated 
i.p. with 200 μl of either PBS or cetuximab (1 mg) twice weekly for up to 
14 days. Tumor size was measured twice weekly using calipers. Tumor 
volume in cubic millimeters was calculated using the formula π/6 × (large 
diameter) × (small diameter)2.
Statistics. For cell proliferation assays, the Student’s t test was used to test 
for significant differences. For qRT-PCR, the paired Student’s t test was 
used to analyze biological triplicates for significance. For xenograft tumors, 
growth curves were compared using 2-way ANOVA, whereas the differences 
in final tumor volumes between groups were compared using the Student’s 
t test. In analyzing the human breast cancer sample microarray dataset, the 
association between raw PRL-3 and PTP1B mRNA expression was analyzed 
using Spearman’s rank test. Further correlation between stratified PRL-3 
expression and PTP1B expression was tested using the Mann-Whitney 
U test. The correlation between PRL-3 expression and cetuximab treatment 
responses (objective response and disease control) was tested using the 
Student’s t test and was further complemented by Fisher’s exact test for 
treatment response rates (ORR, DCR). Similarly, the correlation between 
PRL-3 expression and gefitinib sensitivity/resistance was tested using the 
Student’s t test. Kaplan-Meier analysis, in conjunction with Cox propor-
tional hazard regression analysis, were used to test the correlation between 
PRL-3 expression groups (high or low) and patient survival. Statistical anal-
ysis was performed using the SPSS 15.0 software package (IBM), and P val-
ues less than 0.05 were considered statistically significant.
Study approval. All animal studies were approved by the IACUC of the 
Biological Resource Centre, A*STAR, Singapore.
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medium was then replaced with 10% FBS medium with or without 20 nM 
cetuximab and incubated for 10 days. To quantify colony formation, cells 
were washed twice with ice-cold PBS before fixing in ice-cold 20% methanol 
for 10 minutes. Subsequently, 0.5% crystal violet (w/v) in 25% methanol 
was used to stain colonies for 10 minutes and was thoroughly washed in 
deionized water before image acquisition. To score for actively dividing 
cells, colonies with diameters greater than or equal to 3 mm were counted 
and used in the statistical analysis.
Microarray dataset analysis. We analyzed 3 public gene expression profile 
(GEP) microarray datasets: the GSE12276 dataset consisting of 204 pri-
mary breast cancer specimens from patients with metastatic disease (31); 
the GSE5851 dataset consisting of 80 colorectal cancer specimens taken 
from patients prior to treatment with cetuximab (39); and the GSE4342 
dataset consisting of a panel of NSCLC cell lines analyzed for sensitivity to 
and resistance against gefitinib treatment (41). All datasets were retrieved 
from the Gene Expression Omnibus (GEO) database and processed using 
R scripting as previously described (65). Since all 3 datasets were assayed 
on Affymetrix HG-U133 platforms, we used the average expression level 
for PRL-3/PTP4A3 probe sets (“206574_s_at” and “209695_at”) or PTP1B/
PTPN1 probe sets (“202716_at”, “217686_at”, “217689_at” and “239526_x_
at”) for further analysis. For the GSE12276 dataset, we investigated the 
association between PRL-3 and PTP1B expression, as well as the correlation 
of PRL-3 with disease-free survival. Patients were divided into 2 groups 
(“high” or “low”) based on their PRL-3 mRNA expression levels using the 
highest quartile value as a cutoff point. For the GSE5851 dataset, we ana-
lyzed the correlation between the tumors’ baseline PRL-3 expression prior 
to cetuximab therapy and cetuximab response (as determined according to 
the Response Evaluation Criteria in Solid Tumors [RECIST]) as well as the 
resulting progression-free survival. We adopted the original study’s 4 des-
ignations of cetuximab response (complete response, CR; partial response, 
PR; stable disease, SD; progressive disease, PD) to obtain 1 CR, 5 PR, 19 SD, 
and 43 PD samples (39). The responses for 12 patients could not be deter-
mined due to death before their first radiographic assessment, and these 
patients were thus excluded from our analysis. For the ORRs, patients were 
separated into CR/PR or SD/PD groups and compared. For DCRs, patients 
were separated into CR/PR/SD or PD groups and compared. For survival 
analysis, patients were divided into 2 groups (“high” or “low”) based on 
their PRL-3 mRNA expression levels using their median values as a cutoff 
point. For the GSE4342 dataset, we analyzed the expression levels of PRL-3 
in NSCLC cell lines (listed in Table 1 of the original publication; ref. 41) 
according to the references’ designation of gefitinib-sensitive (IC50 ≤4.5 
μmol/l, n = 15) or gefitinib-resistant (IC50 >4.5 μmol/l, n = 12).
Xenograft experiments. A431-vec or A431-PRL-3 cells (3 × 106) were 
injected s.c. into the left and right hips of 8-week-old nude mice (The 
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